Thursday, December 2, 2021 Daily Archives

A Frost & Sullivan Virtual Think Tank: 3M™ Polisher ST Beta Testing Series

by

One step can change everything: Replace your flow-through AEX column with a novel single-use polishing solution 3M™ Polisher ST single use polishing solution – from lab to manufacturing scale Frost & Sullivan recently invited a panel of bioprocessing industry leaders and key opinion leaders to participate in a Virtual Think Tank (VTT) Early Access series – a new and unique thought leadership forum. Each VTT panel, comprised of professionals from top pharmaceutical companies, contract development and manufacturing organizations (CDMOs) and…

December 2, 2021

Build vs. Buy: A Critical Calculation for Cell Therapy Innovators

by

Cell therapy is proving to be one of the most promising advanced modalities, representing a significant step forward in the treatment of a wide range of challenging diseases and conditions. As a cell therapy candidate advances from discovery through clinical development and ultimately to commercialization, foundational decisions must be made by the product sponsor that will impact both scientific and commercial success. One of the biggest decisions is whether to build a manufacturing facility or outsource to a contract development…

December 2, 2021

Downstream dealmaking: Donaldson buys Solaris, Ecolab closes on Purolite

by

Filtration firm Donaldson Company has acquired Solaris Biotechnology to bolster its presence in the life sciences space. Meanwhile, Ecolab has completed the $3.7 billion acquisition of purification firm Purolite. Minneapolis-based filtration firm Donaldson will add a range of bioreactors, fermenters, and tangential flow filtration systems through the €41 million ($47 million) addition of Italy’s Solaris. “This acquisition is an important step on our journey towards strengthening our presence in the life sciences market,†said Tod Carpenter, CEO of Donaldson. “With…

December 2, 2021

Fujifilm to invest $500m+ in UK CDMO business

by and

Fujifilm Corp has confirmed £400 ($532) million of a previously announced investment program will be spent expanding its CDMO operations in Billingham, UK. According to a plan unveiled today Fujifilm will double the sites development and manufacturing capabilities, establish both a viral gene therapy facility and a mammalian cell culture facility and create up to 350 jobs. Fujifilm Diosynth Biotechnologies will also build a cell culture facility and ramp up antibody-based therapeutics production capacity through the addition of four 2,000…

December 2, 2021